Skip to main content
Robert Negrin, MD, Hematology, Stanford, CA

Robert S Negrin MD


Professor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center

Join to View Full Profile
  • 300 Pasteur DrStanford, CA 94305

  • Phone+1 650-723-4000

  • Fax+1 650-724-6182

Dr. Negrin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Neonatal-Perinatal Medicine, 1988 - 1989
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1987 - 1988
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1984 - 1987
  • Harvard Medical School
    Harvard Medical SchoolClass of 1984

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1985 - 2027
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2006-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming
    Robert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
    Robert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Activation of Regulatory T Cells with IL-2 and TNF-_ to Promote Homing to the Gut and to Improve Acute GvHD Prevention
    Robert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • How to Peer Review a Scientific Paper 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Volunteering Your Skills Overseas 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Other

Authored Content

  • Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Press Mentions

  • Orca Bio Announces the Precision-T Phase 3 Study Is Open and Enrolling Patients at Transplant Centers Across the U.S.
    Orca Bio Announces the Precision-T Phase 3 Study Is Open and Enrolling Patients at Transplant Centers Across the U.S.February 3rd, 2025
  • Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood Cancers
    Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
  • Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting
    Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
  • Join now to see all

Grant Support

  • Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
  • Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
  • Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
  • Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
  • Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
  • Bone Marrow Grafting and Cellular Therapy for Leukemia and LymphomaSTANFORD UNIVERSITY1997–2025
  • Role Of Regulatory T Cells In GVHD, Gvt, And Tolerance InductionNational Heart, Lung, And Blood Institute2010–2011
  • HematopoeticNational Cancer Institute2010–2011
  • NK Cells In GVHD And GVTNational Cancer Institute2008–2011
  • Training Program In Hematopoietic Cell TransplantationNational Heart, Lung, And Blood Institute2001–2011
  • Regulatory T Cells In Allogeneic TransplantationNational Heart, Lung, And Blood Institute2009–2010
  • Prog 8- Hematopoietic Cell Transplantation AndNational Cancer Institute2007–2009
  • Regulatory T Cells Which Allow GVT Without GVHDNational Heart, Lung, And Blood Institute2004–2008
  • Visualizing Tumors And Mechanisms Of Therapy In VivoNational Cancer Institute1999–2007
  • BMT Clinical Trial Network At StanfordNational Heart, Lung, And Blood Institute2002–2003
  • BMT Clinical Trial Netwrok At StanfordNational Heart, Lung, And Blood Institute2001

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: